ESTRO 2024 - Abstract Book

S2637

Clinical - Urology

ESTRO 2024

Statistically significant differences were found between PSA after RP (p= 0.04), PSA after PORT (p= 0.001) and PSA NADIR (p=0.001) and the possibility of recurrence. However, no differences were found between the highest PSA achieved after RP, nor PSA at diagnosis and recurrence. In the anatomopathological characteristics, ISUP 1 presented 7 patients (12.28%), ISUP 2 18 patients (31.58%), ISUP 3 12 patients (21.05%), ISUP 4 6 patients (10.52%) and ISUP 5 14 patients (24.56%). Perineural invasion presented 41 patients (71.93%), lymphovascular invasion 12 (21.05%), positive margins after RP 31 patients (54.39%), extrapsularity 31 patients, VVSS involvement 14 patients and lymph node involvement in 8 patients (14.03%). No differences were found between pathological features and recurrence after PORT. The location of the recurrences was in 26 patients biochemical recurrence (45.61%) since no location was found in imaging tests, in 3 patients local relapse (5.26%), in 3 patients at a single regional lymph node, in 5 patients at a single lymph node at distance (8.77%), in 4 patients at a single bone at distance (7.02%), and in 12 patients were in multiple locoregional and at distance sites (21.05%). The treatment in 36 patients was hormonal blockade (HB) exclusively (63.16%), in 14 patients HB with Stereotactic radiation therapy (SBRT) (24.56%), in 4 patients HB and androgen receptor-targeted agents (ARTA), in 1 patient HB + ARTA + SBRT and in 3 patients chemotherapy (5.26%). 6 patients died of which 4 were cancer dependent (7%).

Conclusion:

Conclusion 36.84% of recurrences were in metastatic locations. Recurrences in bed and regional nodes were isolated. Studies are needed to identify those patients who would benefit from intensified treatment.

Keywords: recurrence, prostate bed, prostate cancer

References:

Tseng CS, Wang YJ, Chen CH, Wang SM, Huang KH, Chow PM, Pu YS, Huang CY, Cheng JC. Outcomes and Prediction Models for Exclusive Prostate Bed Salvage Radiotherapy among Patients with Biochemical Recurrence after Radical Prostatectomy. Cancers (Basel). 2021 May 28;13(11):2672.

Aizawa T, Maebayashi T, Ishibashi N, Sakaguchi M, Sato A, Yamaguchi K. Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery. BMC Urol. 2023 Oct 4;23(1):157

Ishikawa H, Higuchi K, Kaminuma T, Takezawa Y, Saito Y, Etsunaga T, Maruo K, Kawamura H, Kubo N, Nakano T, Kobayashi M. The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy. J Radiat Res. 2020 Nov 16;61(6):908-919.

Gonzalez-Moya A, Supiot S, Seegers V, Lizée T, Legouté F, Perennec T, Calais G. Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients. Front Oncol. 2022 Jan 5;11:787347.

Rowe, L.S., Harmon, S., Horn, A. et al. Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques. Radiat Oncol 16, 32 (2021).